Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
AZTR | US
0.02
12.53%
Healthcare
Biotechnology
30/06/2024
09/03/2026
0.20
0.18
0.21
0.17
Azitra Inc a pre-clinical biopharmaceutical company focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12 a genetically modified strain of S. epidermidis for treating Netherton syndrome a skin disease; ATR-04 a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01 an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris a skin disease. The company was incorporated in 2014 and is based in Branford Connecticut.
View LessStrength based on increasing price with high volume
High Current Volume and Positive 1-Day Return
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
96.8%1 month
100.9%3 months
98.6%6 months
95.9%0.01
-
2.42
0.42
0.19
-0.39
10.02
-
-10.12M
1.55M
1.55M
-
-35.47K
-
-95.60
-222.30
0.78
3.18
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.05
Range1M
0.07
Range3M
0.24
Rel. volume
3.08
Price X volume
1.16M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| BioRestorative Therapies Inc | BRTX | Biotechnology | 0.232 | 1.61M | 8.97% | n/a | 0.77% |
| Lipella Pharmaceuticals Inc. Common Stock | LIPO | Biotechnology | 0.194 | 1.57M | 25.08% | n/a | 5.50% |
| ERNA | ERNA | Biotechnology | 0.283 | 1.53M | -0.70% | n/a | -577.12% |
| Kala Pharmaceuticals Inc | KALA | Biotechnology | 0.2605 | 1.43M | -6.33% | n/a | 268.29% |
| International Stem Cell Corporation | ISCO | Biotechnology | 0.1761 | 1.41M | n/a | 0.00% | |
| XORTX Therapeutics Inc. Common Stock | XRTX | Biotechnology | 0.4599 | 1.38M | -1.88% | n/a | 3.09% |
| RedHill Biopharma Ltd | RDHL | Biotechnology | 0.9241 | 1.18M | 0.45% | n/a | 65.80% |
| Phio Pharmaceuticals Corp | PHIO | Biotechnology | 1.21 | 1.04M | 4.31% | n/a | 0.00% |
| Galmed Pharmaceuticals Ltd | GLMD | Biotechnology | 0.6153 | 927.25K | -6.77% | n/a | 0.00% |
| Evofem Biosciences Inc | EVFM | Biotechnology | 0.009 | 902.96K | 1.12% | 0.00 | 0.00% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 2.46 | 1.36M | 2.93% | n/a | 0.00% |
| Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.008 | 737.72K | n/a | -37.05% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.39 | 0.53 | Cheaper |
| Ent. to Revenue | 10.02 | 3,967.00 | Cheaper |
| PE Ratio | 0.01 | 41.03 | Cheaper |
| Price to Book | 2.42 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 98.60 | 72.80 | Riskier |
| Debt to Equity | 0.42 | -1.23 | Expensive |
| Debt to Assets | 0.19 | 0.25 | Cheaper |
| Market Cap | 1.55M | 3.66B | Emerging |